Where can I buy ACAD shares?
Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ACADIA Pharmaceuticals' stock price today?
What is the ticker symbol for Acadia Pharmaceuticals?
ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD." Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by a variety of retail and institutional investors.
Should you hold Acadia Pharmaceuticals (ACAD) stock?
The consensus among Wall Street analysts is that investors should "hold" ACADIA Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
How much is a share of Acadia worth?
One share of ACAD stock can currently be purchased for approximately $22.26. How much money does ACADIA Pharmaceuticals make? ACADIA Pharmaceuticals has a market capitalization of $3.58 billion and generates $441.76 million in revenue each year.
Is ACAD stock a good buy?
Out of 14 analysts, 2 (14.29%) are recommending ACAD as a Strong Buy, 5 (35.71%) are recommending ACAD as a Buy, 7 (50%) are recommending ACAD as a Hold, 0 (0%) are recommending ACAD as a Sell, and 0 (0%) are recommending ACAD as a Strong Sell. What is ACAD's earnings growth forecast for 2022-2024?
Will ACAD stock go up?
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) The 17 analysts offering 12-month price forecasts for ACADIA Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 32.00 and a low estimate of 10.00. The median estimate represents a +30.89% increase from the last price of 15.28.
Why is ACAD stock dropping?
Rather, investors in Acadia Pharmaceuticals (NASDAQ:ACAD) are feeling pain following a more than 30% drop in ACAD stock. This afternoon's move comes after an FDA panel voted down the company's Nuplazid Alzheimer's psychosis drug.
Why is Acadia dropping?
The recent drop can be attributed to the U.S. FDA finding deficiencies in its application for its psychosis drug - Nuplazid. This is an important update given that Nuplazid sales with the new approval were touted to add as much as $2 billion in incremental sales.
What does Acadia Pharmaceuticals make?
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders.
Is Acadia Pharmaceuticals a good company to work for?
Acadia Pharmaceuticals is ranked #100 on the Best Health Care Companies to Work For in California list. Zippia's Best Places to Work lists provide unbiased, data-based evaluations of companies. Rankings are based on government and proprietary data on salaries, company financial health, and employee diversity.
What is happening with Acadia Pharmaceuticals?
Acadia Pharmaceuticals Crashes After FDA Panel Votes Down Its Alzheimer's Psychosis Drug. Food and Drug Administration experts voted against recommending Acadia Pharmaceuticals' (ACAD) Alzheimer's disease psychosis drug, leading ACAD stock to plummet Tuesday. On today's stock market, ACAD stock collapsed 33.3% to 13.01 ...
Should I buy or sell ACADIA Pharmaceuticals stock right now?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 8 hold ratin...
What is ACADIA Pharmaceuticals' stock price forecast for 2022?
17 Wall Street analysts have issued 12-month price targets for ACADIA Pharmaceuticals' shares. Their forecasts range from $23.00 to $37.00. On aver...
How has ACADIA Pharmaceuticals' stock price performed in 2022?
ACADIA Pharmaceuticals' stock was trading at $23.34 at the beginning of the year. Since then, ACAD stock has decreased by 25.3% and is now trading...
When is ACADIA Pharmaceuticals' next earnings date?
ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast...
How were ACADIA Pharmaceuticals' earnings last quarter?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings results on Wednesday, May, 4th. The biopharmaceutical company reported ($0....
What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?
ACADIA Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the...
Who are ACADIA Pharmaceuticals' key executives?
ACADIA Pharmaceuticals' management team includes the following people: Mr. Stephen R. Davis J.D. , CEO & Director (Age 61, Pay $1.03M) ( LinkedI...
What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?
8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com . Steve Davis has an approval rating of 88% among ACADIA Pharmaceut...
Who are some of ACADIA Pharmaceuticals' key competitors?
Some companies that are related to ACADIA Pharmaceuticals include Elanco Animal Health (ELAN) , Biohaven Pharmaceutical (BHVN) , United Therapeu...
When will ACADIA release its earnings?
How much does Acadia make?
ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021. View our earnings forecast for ACADIA Pharmaceuticals.
Stock Price Forecast
How much money does ACADIA Pharmaceuticals make? ACADIA Pharmaceuticals has a market capitalization of $3.44 billion and generates $441.76 million in revenue each year . The biopharmaceutical company earns $-281,580,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.
Analyst Recommendations
The 19 analysts offering 12-month price forecasts for ACADIA Pharmaceuticals Inc have a median target of 30.00, with a high estimate of 42.00 and a low estimate of 20.00. The median estimate represents a +15.92% increase from the last price of 25.88.
How much did Arcadis repurchase in 2021?
The current consensus among 21 polled investment analysts is to Hold stock in ACADIA Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Hold rating. Move your mouse over past months for detail
What is Arcadis Gen?
Amsterdam, July 9, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 56,614 of its own shares in the period from 2 July up to and including 8 July 2021 at an average price of €35.08. The consideration of this repurchase was €2.0 million.
Is Arcadis a partner of Techstars?
Amsterdam, May 12, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, today announced that Arcadis Gen, its global digital business that provides data-driven products and solutions across the natural and built environment has launched AppliedInsight.
When was Arcadis Gen created?
Arcadis renews partnership with Techstars and joins Sustainability Challenge. Amsterdam, June 2, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, today announced that it is renewing its partnership with Techstars, the worldwide network that helps entrepreneurs succeed, ...
Does Arcadis have a buyback program?
Gen was created in 2020 to further accelerate Arcadis’ industry leading digital transformation with scalable product-based solutions. Arcadis Gen CEO, Rachel White stated: “With the apps available today and many more in development, we’re creating the go-to webstore for the asset management community.